Protagonist Therapeutics (PTGX) Competitors $46.16 +0.36 (+0.79%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. RDY, MRNA, VTRS, QGEN, ASND, ROIV, LNTH, TGTX, RVMD, and BBIOShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), TG Therapeutics (TGTX), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Revolution Medicines BridgeBio Pharma Dr. Reddy's Laboratories (NYSE:RDY) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate RDY or PTGX? Dr. Reddy's Laboratories currently has a consensus target price of $17.00, indicating a potential upside of 24.68%. Protagonist Therapeutics has a consensus target price of $65.44, indicating a potential upside of 41.77%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to RDY or PTGX? In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Dr. Reddy's Laboratories and 10 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.20 beat Dr. Reddy's Laboratories' score of 0.71 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Protagonist Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, RDY or PTGX? Dr. Reddy's Laboratories has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$311.31B0.04$668M$0.6321.64Protagonist Therapeutics$434.43M6.52-$78.96M$4.2010.99 Does the MarketBeat Community favor RDY or PTGX? Dr. Reddy's Laboratories received 30 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. However, 61.65% of users gave Protagonist Therapeutics an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote. CompanyUnderperformOutperformDr. Reddy's LaboratoriesOutperform Votes32159.33% Underperform Votes22040.67% Protagonist TherapeuticsOutperform Votes29161.65% Underperform Votes18138.35% Which has more risk and volatility, RDY or PTGX? Dr. Reddy's Laboratories has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Is RDY or PTGX more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Dr. Reddy's Laboratories' net margin of 17.25%. Protagonist Therapeutics' return on equity of 34.68% beat Dr. Reddy's Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories17.25% 17.87% 12.32% Protagonist Therapeutics 52.76%34.68%30.98% Do insiders & institutionals hold more shares of RDY or PTGX? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryProtagonist Therapeutics beats Dr. Reddy's Laboratories on 14 of the 19 factors compared between the two stocks. Remove Ads Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.84B$6.46B$5.30B$7.37BDividend YieldN/A3.24%5.11%4.31%P/E Ratio17.386.8221.6917.76Price / Sales6.52227.25377.9494.24Price / CashN/A65.6738.1534.64Price / Book7.905.856.413.98Net Income-$78.96M$142.26M$3.20B$247.41M7 Day Performance12.90%7.31%4.61%4.22%1 Month Performance-12.92%-14.38%-9.97%-7.89%1 Year Performance80.54%-9.85%10.75%1.25% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics3.7802 of 5 stars$46.16+0.8%$65.44+41.8%+75.4%$2.84B$434.43M17.38120News CoveragePositive NewsRDYDr. Reddy's Laboratories2.2332 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.2421 of 5 stars$25.64+2.1%$59.00+130.1%-75.7%$9.91B$3.20B-2.763,900Analyst ForecastVTRSViatris2.9827 of 5 stars$7.61-0.1%$10.50+38.0%-33.5%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.3853 of 5 stars$40.33+5.4%$47.71+18.3%+8.4%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S3.0645 of 5 stars$140.14-1.8%$204.64+46.0%+11.8%$8.50B$363.64M-19.741,017Analyst ForecastPositive NewsROIVRoivant Sciences2.6416 of 5 stars$9.26-2.1%$17.50+89.0%-6.4%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3457 of 5 stars$95.45+5.0%$129.43+35.6%+62.8%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.3581 of 5 stars$37.25-0.3%$40.67+9.2%+172.9%$5.85B$329.00M-372.46290Positive NewsRVMDRevolution Medicines3.7285 of 5 stars$31.40+0.3%$65.23+107.7%-0.1%$5.84B$742,000.00-8.75250Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.6139 of 5 stars$30.67-2.2%$52.64+71.6%+34.1%$5.83B$221.90M-10.76400Analyst ForecastInsider TradeAnalyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Ascendis Pharma A/S Alternatives Roivant Sciences Alternatives Lantheus Alternatives TG Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts